Strides Pharma Global, the wholly-owned subsidiary of Strides Shasun, has received final approval for Cinacalcet Hydrochloride tablets from the US FDA. Cinacalcet Hydrochloride tablets is a generic version of Sensipar tablets of Amgen, a US-based company. It is used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and other forms of thyroid. The product is part of the backward integrated formulations portfolio and will receive API supplies from Solara Active Pharma Sciences under a long-term manufacturing agreement. The product will be manufactured at the company’s oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc in the US.

comment COMMENT NOW